Your session is about to expire
← Back to Search
Patient Navigation Program for Chronic Diseases (ENCOMPASS Trial)
N/A
Waitlist Available
Led By Kerry A McBrien, MD, MPH
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Established ischemic heart disease
Congestive heart failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6- and 12-months post-implementation
Awards & highlights
ENCOMPASS Trial Summary
This trial is evaluating a patient navigation program to see if it can help improve care and health outcomes for high-risk patients with chronic disease.
Who is the study for?
This trial is for adults over 18 with chronic diseases like severe lung conditions, heart failure, high blood pressure, kidney disease, or poorly controlled diabetes. They must have had multiple visits for their condition in the past year and be able to give informed consent. It's not open to those in long-term care facilities or if a doctor thinks it's not suitable.Check my eligibility
What is being tested?
The ENCOMPASS Intervention is being tested. It pairs patients with complex health issues with community health navigators who help them understand and manage their conditions better by improving communication with healthcare providers and navigating the health system.See study design
What are the potential side effects?
Since this intervention involves patient education and support rather than medication, traditional side effects are not expected. However, there may be indirect effects on stress levels or emotional well-being due to changes in healthcare management.
ENCOMPASS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with heart disease caused by narrowed heart arteries.
Select...
I have been diagnosed with congestive heart failure.
Select...
I have COPD or asthma and visited a doctor for it at least twice last year.
Select...
My kidney function is reduced, with an eGFR below 45 mL/min/1.73m2 in the last year.
Select...
My diabetes has been poorly controlled, with an A1C over 9% in the past year.
Select...
I am 18 years old or older.
ENCOMPASS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6- and 12-months post-implementation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6- and 12-months post-implementation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Acute care utilization
Secondary outcome measures
Acute care costs
Anxiety score
Depression score
+17 moreENCOMPASS Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ENCOMPASS programExperimental Treatment1 Intervention
Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
Group II: Usual careActive Control1 Intervention
Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
791 Previous Clinical Trials
868,558 Total Patients Enrolled
Canadian Diabetes AssociationOTHER
42 Previous Clinical Trials
11,146 Total Patients Enrolled
Alberta Innovates Health SolutionsOTHER
52 Previous Clinical Trials
94,069 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with heart disease caused by narrowed heart arteries.You live in a long-term care facility.I have been diagnosed with congestive heart failure.I am unable to understand and give consent for treatment.I have COPD or asthma and visited a doctor for it at least twice last year.The doctor will decide.Your blood pressure is not well controlled, and your most recent systolic blood pressure was higher than 160 mmHg.My kidney function is reduced, with an eGFR below 45 mL/min/1.73m2 in the last year.My diabetes has been poorly controlled, with an A1C over 9% in the past year.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: ENCOMPASS program
- Group 2: Usual care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available openings for participants in this experiment?
"Affirmative. The data on clinicaltrials.gov shows that the recruitment for this medical trial is ongoing, having been initially posted on May 1st 2018 and updated most recently in May 19th 2022. 1600 patients are sought from a single location."
Answered by AI
What is the maximum amount of participants that can partake in this research?
"Affirmative. Per the information hosted on clinicaltrials.gov, this trial is still actively recruiting participants and was originally published in May 2018 with a recent amendment made to it on May 19th 2022. The study requires 1600 patients at one medical site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger